AU3552697A - Novel treatment of leptine resistance - Google Patents

Novel treatment of leptine resistance

Info

Publication number
AU3552697A
AU3552697A AU35526/97A AU3552697A AU3552697A AU 3552697 A AU3552697 A AU 3552697A AU 35526/97 A AU35526/97 A AU 35526/97A AU 3552697 A AU3552697 A AU 3552697A AU 3552697 A AU3552697 A AU 3552697A
Authority
AU
Australia
Prior art keywords
leptine
resistance
novel treatment
novel
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU35526/97A
Inventor
George Henry Poste
Stephen Alistair Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614751.7A external-priority patent/GB9614751D0/en
Priority claimed from GBGB9614740.0A external-priority patent/GB9614740D0/en
Priority claimed from GBGB9616412.4A external-priority patent/GB9616412D0/en
Priority claimed from GBGB9616407.4A external-priority patent/GB9616407D0/en
Priority claimed from GBGB9616409.0A external-priority patent/GB9616409D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU3552697A publication Critical patent/AU3552697A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AU35526/97A 1996-07-12 1997-07-14 Novel treatment of leptine resistance Abandoned AU3552697A (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GBGB9614751.7A GB9614751D0 (en) 1996-07-12 1996-07-12 Novel treatment
GBGB9614740.0A GB9614740D0 (en) 1996-07-12 1996-07-12 Novel treatment
GB9614751 1996-07-12
GB9614740 1996-07-12
GB9616409 1996-08-05
GBGB9616412.4A GB9616412D0 (en) 1996-08-05 1996-08-05 Novel treatment
GBGB9616407.4A GB9616407D0 (en) 1996-08-05 1996-08-05 Novel treatment
GBGB9616409.0A GB9616409D0 (en) 1996-08-05 1996-08-05 Novel treatment
GB9616412 1996-08-05
GB9616407 1996-08-05
PCT/GB1997/001928 WO1998002159A1 (en) 1996-07-12 1997-07-14 Novel treatment of leptine resistance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU72170/00A Division AU7217000A (en) 1996-07-12 2000-12-11 Novel treatment of leptin resistance

Publications (1)

Publication Number Publication Date
AU3552697A true AU3552697A (en) 1998-02-09

Family

ID=27517363

Family Applications (1)

Application Number Title Priority Date Filing Date
AU35526/97A Abandoned AU3552697A (en) 1996-07-12 1997-07-14 Novel treatment of leptine resistance

Country Status (12)

Country Link
EP (1) EP0921798A1 (en)
JP (1) JP2000514807A (en)
KR (1) KR20000023719A (en)
CN (1) CN1230114A (en)
AU (1) AU3552697A (en)
BR (1) BR9710272A (en)
CA (1) CA2260044A1 (en)
NO (1) NO990097L (en)
PL (1) PL331148A1 (en)
TR (1) TR199900056T2 (en)
TW (1) TW442288B (en)
WO (1) WO1998002159A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
WO1999044598A2 (en) * 1998-03-03 1999-09-10 Board Of Regents, The University Of Texas System Methods for inhibiting βcell apoptosis
IL146104A0 (en) 1999-04-28 2002-07-25 Reddy Research Foundation Substituted bicyclic heterocyclic compounds, processes for their preparation and pharmaceutical compositions containing the same
CA2440680C (en) 2001-03-12 2010-06-01 Roberto Pellicciari Steroids as agonists for fxr
WO2002080936A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
SI1734970T1 (en) 2004-03-12 2015-04-30 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
ITMI20050912A1 (en) 2005-05-19 2006-11-20 Erregierre Spa PROCESS OF PREPARATION OF ACIDS 3-A-YA (B) -DIDROSSI-6-A (B) -ALCHIL-5B-COLANICI
EA017714B1 (en) 2007-01-19 2013-02-28 Интерсепт Фармасьютикалз, Инк. Tgr5 modulators and methods of use thereof
BRPI0916735B8 (en) 2008-07-30 2021-05-25 Intercept Pharmaceuticals Inc tgr5 modulating compounds, pharmaceutical compositions comprising them and their uses
DK2698375T3 (en) 2008-11-19 2018-05-28 Intercept Pharmaceuticals Inc TGR5 modulators and methods for using them
KR101881245B1 (en) 2012-06-19 2018-07-23 인터셉트 파마슈티컬즈, 인크. Preparation, uses and solid forms of obeticholic acid
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051189A (en) * 1983-08-30 1985-03-22 Sankyo Co Ltd Thiazolidine derivative and its preparation
EP0601001B1 (en) * 1991-08-26 1997-04-16 PHARMACIA & UPJOHN COMPANY Liquid food product containing 3-guanidinopropionic acid
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
BR9710272A (en) 1999-08-10
TR199900056T2 (en) 1999-04-21
KR20000023719A (en) 2000-04-25
CN1230114A (en) 1999-09-29
TW442288B (en) 2001-06-23
CA2260044A1 (en) 1998-01-22
JP2000514807A (en) 2000-11-07
WO1998002159A1 (en) 1998-01-22
NO990097D0 (en) 1999-01-11
NO990097L (en) 1999-01-11
PL331148A1 (en) 1999-06-21
EP0921798A1 (en) 1999-06-16

Similar Documents

Publication Publication Date Title
AUPO203996A0 (en) Therapeutic uses
EP0815838A3 (en) External skin treatment composition
AU2207797A (en) Human bikunin
AU7772794A (en) Treatment of obesity
AU2972497A (en) Treatment of oils
AU3552697A (en) Novel treatment of leptine resistance
AU5383498A (en) Human chemokine beta-13
AU1251197A (en) Treatment of liquors
AUPO434196A0 (en) An improved therapeutic
AUPO071296A0 (en) Heating of components
AU2870597A (en) Treatment of liquid
AU2068295A (en) Skin treatment composition
AU1926597A (en) Treatment of cocoa
AU5621798A (en) Human pathogenesis-related protein
AU1933297A (en) Manufacture of elongate members
AU4027097A (en) Method of treatment
AU4744997A (en) Novel human phospholemman-like protein
AU1289695A (en) Human stanniocalcin-alpha
AU696976B2 (en) Effluent treatment
AU4885397A (en) Aids therapeutic composition
AU3040797A (en) Preparation of alpha-fluoroketones
IL127906A0 (en) Novel treatment of leptine resistance
AU4310397A (en) Treatment of waste
AU4124497A (en) Treatment of diabetes
AUPO108596A0 (en) Treatment of obesity

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted